AbbVie’s Venclexta Fails In Combo AML Trial

Pfizer’s Daurismo May Benefit From Venclexta’s VIALE-C Setback

 
• By Sten Stovall
  
AML
Venclexta missed VIALE-C Phase III endpoints in acute myeloid leukemia • Source: Shutterstock

More from Clinical Trials

More from R&D